Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Diabetes Technol Ther. 2011 Feb;13(2):143-8. doi: 10.1089/dia.2010.0048.
This study was designed to determine the effect of exenatide on inflammatory and oxidative stress markers in type 2 diabetes mellitus (T2DM) patients who were suboptimally controlled with metformin and/or sulfonylurea.
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients). Glycosylated hemoglobin (HbA1c), the seven-point glucose profile, daily mean glucose, and glycemic excursion were determined. The effects of exenatide on 8-iso-prostaglandin F2α (PGF2α), monocyte chemoattractant protein-1 (MCP-1), and high-sensitivity C-reactive protein (hs-CRP) were investigated.
Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05). Limited glycemic excursion was found in the E group compared with the P group (P < 0.05), including a smaller SD and postprandial glucose excursion. In addition, the oxidative stress maker PGF2α was significantly reduced by exenatide treatment (P < 0.05). The inflammatory markers hs-CRP and MCP-1 were also significantly reduced in the E group compared with the P group (P < 0.05). PGF2α was significantly correlated with glycemic excursion (P < 0.05), whereas MCP-1 was significantly correlated with body weight, BMI, glycemic excursion, and HbA1c (P < 0.05 for all).
Exenatide treatment reduced patient body weight and BMI, improved HbA1c and the seven-point glucose profile, reduced daily mean glucose, limited glycemic excursion, and reduced oxidative stress and inflammatory markers in patients of T2DM having inadequate glucose control.
本研究旨在观察艾塞那肽对二甲双胍和（或）磺脲类药物控制不佳的 2 型糖尿病（T2DM）患者的炎症和氧化应激标志物的影响。
将 23 例血糖控制不佳的 T2DM 患者随机分为两组：艾塞那肽组（E 组）（12 例，5μg，每日 2 次×4 周，随后 10μg，每日 2 次×12 周）和安慰剂组（P 组）（11 例）。测定糖化血红蛋白（HbA1c）、七点血糖谱、平均日血糖和血糖波动。研究艾塞那肽对 8-异前列腺素 F2α（PGF2α）、单核细胞趋化蛋白-1（MCP-1）和高敏 C 反应蛋白（hs-CRP）的影响。
与安慰剂组相比，艾塞那肽治疗降低了体重和体重指数（BMI），并改善了 HbA1c、七点血糖谱和平均日血糖（P<0.05）。与 P 组相比，E 组的血糖波动幅度较小，包括血糖标准差和餐后血糖波动幅度（P<0.05）。此外，艾塞那肽治疗显著降低了氧化应激标志物 PGF2α（P<0.05）。与 P 组相比，E 组的炎症标志物 hs-CRP 和 MCP-1 也显著降低（P<0.05）。PGF2α与血糖波动显著相关（P<0.05），而 MCP-1与体重、BMI、血糖波动和 HbA1c 显著相关（P<0.05）。
艾塞那肽治疗可降低 T2DM 患者的体重和 BMI，改善 HbA1c 和七点血糖谱，降低平均日血糖，限制血糖波动幅度，降低氧化应激和炎症标志物。
